CASE REPORTS in
HAEMATOLOGY (Paper co-edited with the European LeukemiaNet) |
Dic(1;15)(p11;p11) as a non-random abnormality in essential thrombocytemia |
Written | 2008-05 | Olivier Theisen, Steven Richebourg, Jean-Luc Lai, Catherine Roche-Lestienne |
Laboratoire de Genetique Medicale, Hopital Jeanne de Flandre, CHRU de Lille, France (OT, SR, JLL, CRL); Institut de Recherche sur le Cancer, Centre JP Aubert, Unite Inserm 837, Lille, France (JLL, CRL) |
Clinics |
Age and sex : | 74 year(s) old female patient. |
Previous History : | no preleukemia |
no previous malignant disease | |
no inborn condition of note |
Organomegaly : no hepatomegaly ; no splenomegaly ; no enlarged lymph nodes ; no central nervous system involvement |
Blood |
WBC : 16.4 x 109/L ; Hb : 16.3 g/dL ; platelets : 872 x 109/L; |
Cyto pathology classification |
Cytology : - |
Immunophenotype : - |
Rearranged Ig Tcr : - |
Pathology : MPD |
Electron microscopy : - |
Precise diagnosis : Essential Thrombocytemia |
Survival |
Date of diagnosis: 03-1997 |
Treatment : Hydroxyurea |
Complete remission : None |
Treatment related death : - |
Relapse : - |
Status : Dead 02-2008 |
Survival : 131 month(s) |
Karyotype |
Sample : bone marrow ; culture time : 48 h ; banding : GTG |
Results : 46,XX,[3]/46,XX,-15,+dic(1;15)(p11;p11)[10] |
Karyotype at relapse : NA |
Other molecular cytogenetics technics : NA |
Other molecular studies |
technics : NA |
Other findings |
results : NA |
![]() |
Karyotype at diagnosis presenting the dic(1;15)(p11;p11) as sole abnormality. |
Comments |
This is an additional MPD case presenting this recurrent abnormality, with 11 years survival. However the death is not related to the disease (cardiac failure) in this case. |
Internal links |
Citation |
This paper should be referenced as such : |
Free journal version : [ pdf ] [ DOI ] |
On line version : http://AtlasGeneticsOncology.org/Reports/dic115inETRocheID100036.html |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Sat Dec 5 19:11:59 CET 2020 |
For comments and suggestions or contributions, please contact us